1241679-91-3

Usage

Uses

Used in Pharmaceutical Industry:
(1R)-1-(4-BROMO-3-FLUOROPHENYL)ETHYLAMINE is used as a building block for the synthesis of various pharmaceuticals and research chemicals. Its unique structural features and pharmacological properties make it a promising candidate for the development of new drugs and therapeutic agents.
Used in Medicinal Chemistry Research:
(1R)-1-(4-BROMO-3-FLUOROPHENYL)ETHYLAMINE is used as a valuable intermediate in the production of biologically active compounds. Its presence as a key component in the synthesis of various compounds allows researchers to explore its potential applications in the discovery and development of novel therapeutic agents.
Used in Drug Development:
(1R)-1-(4-BROMO-3-FLUOROPHENYL)ETHYLAMINE is utilized in drug development processes to create new pharmaceuticals with potential therapeutic benefits. Its unique characteristics, including the presence of bromine and fluorine atoms on the phenyl ring, contribute to its role as an important intermediate in the synthesis of biologically active compounds.

Upstream product

• 304445-49-6 1-(4-bromo-3-fluorophenyl)ethan-1-one 
• 695188-21-7 4-bromo-3-fluorobenzoyl chloride 
• 153556-42-4 4-bromo-3-fluorobenzoic acid 
• 343564-56-7 4-bromo-3-fluoro-N-methoxy-N-methyl-benzamide 
• 1444780-23-7 2-methyl-propane-2-sulfonic acid 4-bromo-3-fluoro-benzylideneamide 
• 1444780-35-1 2-methyl-propane-2-sulfonic acid [1-(4-bromo-3-fluoro-phenyl)-ethyl]-amide 
• 133059-43-5 4-bromo-3-fluorobenzaldehyde 

Relevant academic research and scientific papers

ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR

Disclosed are compounds inhibiting the conversion of α–KG to D-2-HG, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition c

3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH

The invention is directed to a formula (I), or a pharmamceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

NEW PIPERIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

The invention relates to new piperidine derivatives of the formula (I) to their use as medicaments, to methods for their therapeutic use as inhibitors of acetyl-CoA carboxylases and to pharmaceutical compositions containing them.

NEW AZIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS

The invention relates to new azetidine derivatives of the formula (I) wherein Ar1, Ar2, X, R, T and L are as defined in the description, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.